Secondary Logo

Institutional members access full text with Ovid®

Therapy With Mesenchymal Stem Cells in Parkinson Disease: History and Perspectives

Mendes Filho, Daniel, MSc*,†; Ribeiro, Patrícia d.C., MSc†,‡; Oliveira, Lucas F., PhD*,§; de Paula, Diógenes R.M., MSc*; Capuano, Vanessa, PhD*; de Assunção, Thaís S.F., MSc‖,¶; da Silva, Valdo J.D., MD, PhD*,‖

doi: 10.1097/NRL.0000000000000188
Review Article
Buy
SDC

Background: Parkinson disease (PD) is a neurodegenerative disorder affecting the basal nuclei, causing motor and cognitive disorders. Bearing in mind that standard treatments are ineffective in delaying the disease progression, alternative treatments capable of eliminating symptoms and reversing the clinical condition have been sought. Possible alternative treatments include cell therapy, especially with the use of mesenchymal stem cells (MSC).

Review Summary: MSC are adult stem cells which have demonstrated remarkable therapeutic power in parkinsonian animals due to their differentiation competence, migratory capacity and the production of bioactive molecules. This review aims to analyze the main studies involving MSC and PD in more than a decade of studies, addressing their different methodologies and common characteristics, as well as suggesting perspectives on the application of MSC in PD.

Conclusions: The results of MSC therapy in animal models and some clinical trials suggest that such cellular therapy may slow the progression of PD and promote neuroregeneration. However, further research is needed to address the limitations of an eventual clinical application.

Departments of *Physiology, Biological and Natural Sciences Institute

Tropical Medicine and Infectiology, Health Sciences Institute, Triângulo Mineiro Federal University, Uberaba

Nanocell Institute, Divinópolis, MG

Laboratory of Immunology and Experimental Transplantation, São José do Rio Preto Medical School, São José do Rio Preto, SP

§National Institute of Science and Technology for Regenerative Medicine (INCT-REGENERA-CNPq), Rio de Janeiro, RJ

Minas Gerais Network for Tissue Engineering and Cell Therapy (REMETTEC-FAPEMIG), Belo Horizonte, MG, Brazil

The authors declare no conflict of interest.

Reprints: Valdo J.D. da Silva, MD, PhD, Laboratory of Physiology, Triângulo Mineiro Federal University, Biological and Natural Sciences Institute, Praça Manoel Terra, 330, Uberaba CEP 38025-015, MG, Brazil. E-mail: valdo@mednet.com.br.

Copyright © 2018 Wolters Kluwer Health, Inc. All rights reserved.